The California Association of Health Facilities (CAHF) has selected Darmiyan, Inc., a leading neurotechnology company, as its only Preferred Provider for Cognitive Health Solutions. Through this ...
SAN FRANCISCO, Sept. 16, 2024 /PRNewswire/ -- Darmiyan, Inc., a pioneer in brain technology, is proud to announce the launch of the BrainSee Platform, integrating the first-of-its-kind FDA-approved ...
The Food and Drug Administration has granted de novo authorization to artificial intelligence (AI) diagnostic tools from Imvaria and Darmiyan. Imvaria received authorization for a tool that analyzes ...
SAN FRANCISCO, May 29, 2025 /PRNewswire/ -- Darmiyan, Inc., a leading brain health technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's ...
Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More The brain is a complex beast. It has 100 billion nerve cells — called ...
The US government has reportedly approved AI-based memory loss prediction software for the first time. Darmiyan, a San Francisco-based brain imaging analytics company, says the FDA has granted De Novo ...
Darmiyan, Inc., a leading company in brain health innovation, announces the US FDA's approval of its first-in-class (De Novo) clinical test, BrainSee. This approval marks a pivotal advancement in ...
The collaboration enables CAHF members to access BrainSee™, the only FDA-approved, AI-powered prognostic tool that assesses the risk of progression to clinical Alzheimer's within five years, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback